Initial identification and characterization of sigma receptors on human peripheral blood leukocytes.
Phencyclidine (PCP) has been reported to suppress a variety of immune functions in vitro. Because PCP binds with high affinity to both PCP and sigma receptors, the identity of the receptor(s) mediating the immunological effects of PCP is unknown. The aim of the present study was to identify and characterize the sites of PCP action (sigma and/or PCP receptors) in human peripheral blood leukocytes (PBL) using [3H]haloperidol or 1,3 di(2-([5-3H]tolyl)guanidine ([3H]DTG) to specifically label sigma receptors and 3,4-[3H]-(N)-[1-(2-thienyl)-cyclohexyl]-piperidine ([3H]TCP) to specifically label PCP receptors. [3H]Haloperidol binding was saturable and of high affinity with comparable KD values in human PBL (0.44 +/- 0.10 nM) and rat cerebellum (0.51 +/- 0.09 nM). Similarly, [3H]DTG binding was saturable with comparable KD values of 29.5 +/- 3.5 and 26.4 +/- 3.6 nM in rat cerebellum and human PBL, respectively. In contrast, there was a notable absence of [3H]TCP-labeled PCP receptors in human PBL and rat cerebellum. In competition studies, the pharmacologic profile of [3H]haloperidol-labeled sigma receptors in human PBL was virtually identical with that in rat cerebellum (slope, 0.87; correlation coefficient, 0.96); the rank order of potency of competing drugs was haloperidol greater than l-butaclamol = pentazocine greater than d-3-(hydroxyphenyl)-N-(1-propyl)-piperidine greater than DTG = d-butaclamol = d-SKF 10,047 greater than levallorphan greater than or equal to PCP greater than or equal to l-SKF 10,047 greater than TCP greater than MK-801.(ABSTRACT TRUNCATED AT 250 WORDS)
Wolfe
S A
SA
Neuroscience Branch, National Institute on Drug Abuse, Baltimore, Maryland.
Kulsakdinun
C
C
Battaglia
G
G
Jaffe
J H
JH
De Souza
E B
EB
D000818:Animals; D006146:Guanidines / Q000378:metabolism; D006220:Haloperidol / Q000378:metabolism; D007962:Leukocytes / Q000032:analysis*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D010622:Phencyclidine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000032:analysis; D017448:Receptors, Dopamine D2; D017981:Receptors, Neurotransmitter / Q000032:analysis; D011957:Receptors, Opioid / Q000032:analysis* / Q000187:drug effects; D017478:Receptors, Phencyclidine; D017480:Receptors, sigma; D012559:Schizophrenia / Q000276:immunology
D006146:Guanidines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D017478:Receptors, Phencyclidine; D017480:Receptors, sigma; C012058:tenocyclidine; D010622:Phencyclidine; D006220:Haloperidol; C050232:1,3-ditolylguanidine